# Full title: Diagnostic performance of lateral flow immunoassays for COVID-19 antibodies in Peruvian population

# Short title: Lateral flow immunoassays for COVID-19

Rodrigo Calderon-Flores<sup>1</sup> Guillermo Caceres-Cardenas<sup>1</sup> Karla Alí<sup>1</sup> Margaretha De Vos<sup>2</sup> Devy Emperador<sup>2</sup> Tatiana Cáceres<sup>1</sup> Anika Eca<sup>1</sup> Luz Villa<sup>1</sup> Audrey Albertini<sup>2</sup> Jilian A. Sacks<sup>2</sup> Cesar Ugarte-Gil<sup>1,3</sup>

- 1. Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima Perú
- 2. FIND, the global alliance for diagnostics, Geneva Switzerland
- 3. School of Medicine, Universidad Peruana Cayetano Heredia, Lima Perú

# **Corresponding Author**

Cesar Ugarte-Gil, MD, PhD Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cavetano Heredia, Lima Perú Email: cesar.ugarte@upch.pe

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## ABSTRACT (300 words)

**Background:** Serological assays have been used in seroprevalence studies to inform the dynamics of COVID-19. Lateral flow immunoassay (LFIA) tests are a very practical technology to use for this objective; however, one of their challenges may be variable diagnostic performance. Given the numerous available LFIA tests, evaluation of their accuracy is critical before real-world implementation.

**Methods:** We performed a retrospective diagnostic evaluation study to independently determine the diagnostic accuracy of 4 different antibody-detection LFIA tests. The sample panel was comprised of specimens collected and stored in biobanks; specifically, specimens that were RT-PCR positive for SARS-CoV-2 collected at various times throughout the COVID-19 disease course and those that were collected before the pandemic, during 2018 or earlier, from individuals with upper respiratory symptoms but were negative for tuberculosis. Clinical performance (sensitivity and specificity) was analyzed overall, and subset across individual antibody isotypes, and days from symptoms onset.

**Results:** A very high specificity (98% - 100%) was found for all four tests. Overall sensitivity was variable, ranging from 29% [95% CI: 21%-39%] to 64% [95% CI: 54%-73%]. When considering detection of IgM only, the highest sensitivity was 42% [95% CI: 32%-52%], compared to 57% [95% CI: 47%-66%] for IgG only. When the analysis was restricted to at least 15 days since symptom onset, across any isotype, the sensitivity reached 90% for all four brands.

**Conclusion:** All four LFIA tests proved effective for identifying COVID-19 antibodies when two conditions were met: 1) at least 15 days have elapsed since symptom onset and 2) a sample is considered positive when either IgM or IgG is present. With these considerations, the use of this assays could help in seroprevalence studies or further exploration of its potential uses.

#### BACKGROUND

Since December 2019, the COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a devastating impact on the world population, killing and infecting more than 6.5 and 625 million people as of October 2022 (1). To stop the spread of this pandemic, there are multiple types of COVID-19 tests which have various intended uses. Briefly, reverse transcription polymerase chain reaction (RT-PCR), and other nucleic acid amplification tests, have been shown to have the highest sensitivity and specificity for diagnosis, but can be costly (2); for lower-cost and more rapid diagnosis, antigen rapid diagnostic tests (AgRDT) have been utilized (3); as well, assays that detect SARS-CoV-2-specific antibodies, i.e. serological testing, may be considered for research, monitoring or diagnostic purposes (4).

After acquiring SARS-CoV-2 infection, a person normally develops a humoral immune response including the production of antibodies against certain viral antigens such as the nucleocapsid (N) protein and the spike (S) protein (5,6). On average, IgM and IgG antibodies against viral proteins (N and S) can be detected in serum samples after the first week from symptom onset, although this can vary depending on the host and test characteristics (7,8). Similarly, when deciding between RT-PCR and AgRDTs, there are some aspects to consider when choosing an antibody test.

Currently, there are four methods for antibody detection: lateral flow immunoassay (LFIA), chemiluminescence immunoassays (CLIA), enzyme-linked immunosorbent type assays (ELISA) (9), and antibody neutralization test (4). Of these, the LFIA is the fastest, with the lowest cost and simplest method to detect antibodies; however, this methodology has been shown to have the lowest sensitivity (10). Of note, neutralization assays have been recognized as a proxy for protective immunity to SARS-CoV-2 (11,12). Thus, though LFIA antibody detection may enable rapid reporting of previous virus exposure (through infection or

vaccination), these tests have presented different challenges, including inappropriate use cases (13), underscoring the importance of recognizing the strengths and limitations of antibody testing using this test format to inform their optimal use.

During the early stages of the pandemic, countries such as Peru (14–17), Puerto Rico, Venezuela, and Ecuador, implemented the antibody testing to detect active COVID-19 cases (18), as molecular testing was not readily available due to critical logistic limitations. Unfortunately, antibody expression is limited during the first week of infection, thereby the window of opportunity to efficiently detect infection, isolate and stop transmission chains was lost. In addition, these tests went under minimal to no external validation, affecting the interpretation of their results (13). Over time, countries steadily increased the use of direct virological detection methods using molecular testing and AgRDTs for diagnosis, and used antibody testing for other purposes.

There are roles -albeit with some limitations- for the use of antibody testing. Currently, these tests are commonly used as a tool for seroprevalence studies (19–21), contributing to the understanding of the immune response to the virus (22). Even with the advent of vaccines, depending on the vaccine platform used, antibody testing can also be used to distinguish between vaccinated and non-vaccinated individuals (23–25). This is because vaccines generate an immune response towards a specific protein (e.g. the S subunit antigen of the virus); as a consequence, we can use tests that detect antibodies against S subunits to evaluate vaccination status and tests that detect antibodies against N subunit to evaluate past or recent infection status. Additionally, a series of studies have evaluated the association between quantitative antibody tests and neutralizing antibody tests to determine if the former tests could also have a role in detecting protective immunity (26–29). More innovatively, a study has evaluated an LFIA antibody test coupled with a spectrum-based reader for neutralizing antibodies detection and found a high correlation with a surrogate neutralization test (30,31).

As there is still room for use and further research on antibody testing, every manufacturer must make a thorough evaluation of its test, and this should be followed by independent validations of the test. In this study, we evaluated the accuracy of four LFIA antibody tests by using pre-pandemic samples and PCR-confirmed COVID-19 samples. Our results contribute to the validation of these tests brands to be used in seroprevalence studies and further evaluate its correlation with protective immunity or ability to detect vaccination/past infection status.

#### METHODS

#### Study design:

This was a retrospective diagnostic evaluation study to independently determine the accuracy of 4 different LFIA antibody rapid tests (RTs) using de-identified samples from a biobank collection. The 4 included tests were: Now Check IgM/IgG (Bionote), CareStartTM IgM/IgG (Access Bio), Covid-19 BSS IgG/IgM (Biosynex SA), OnSiteTM IgG/ IgM (CTK Biotech, Inc).

#### Study setting:

The study was conducted in February 2021 at the Instituto de Medicina Tropical Alexander von Humboldt (IMTAvH) from the Universidad Peruana Cayetano Heredia in Lima, Peru.

#### Study samples and sample size:

Samples came from biobank collections. 100 SARS-CoV-2 Positive serum specimens were used from a FIND biobank collection, located at UPCH. Collected between August 2020 and June 2021, these samples come from participants who were confirmed to be infected with

SARS-CoV-2 by documentation of a patient-matched positive RT-PCR test using a respiratory specimen such as an oropharyngeal (OP) swab. Samples were further categorized into subgroups according to days from symptom onset (d.f.s.o): samples collected within 0-7 days, 8-14 days, and 15+ days from symptom onset.

100 negative samples were obtained from stored sample banks collected through tuberculosis studies carried out by FIND with IMTAvH over the last 5 years, from individuals who presented with upper respiratory symptoms but tested negative for tuberculosis. Samples were obtained before November 2019, prior to the introduction of SARS-CoV-2 and thus are from participants who are not expected to have had any exposure to SARS-CoV-2.

The sample size was determined to have reasonable confidence and precision to estimate the performance of each index test for the detection of SARS-CoV-2-specific antibodies. Using 100 RT-PCR positives and 100 COVID-negative samples would yield the following confidence/precision to describe performance (Table 1).

Sensitivity/Specificity	95% CI
99%	+/- 3%
95%	+/- 5%
90%	+/- 6%
85%	+/- 7%
75%	+/- 8.5%

 Table 1. Estimated precisions and confidence intervals based on the proposed sample size.

## Study procedures:

All personnel were previously trained in the use of the kits, following the manufacturer supplied instructions for use. The main objective was to evaluate the sensitivity and clinical specificity

of the COVID-19 antibody LFIA tests and determine the association of index test sensitivity by day from symptom onset.

In order to determine the clinical performance of the test, we established two categories for comparison:

- COVID-19 positive: using plasma from a patient-matched positive RT-PCR test using a respiratory specimen such as an OP swab.
- COVID-19 negative: using negative plasma samples obtained in 2018 or earlier.

#### Statistical analysis:

Index test clinical performance was calculated in comparison to the sample's COVID-19 positivity or negativity status (according to cohort). Analysis was performed for individual antibody isotypes and overall antibody positivity (if either IgM or IgG was positive), if applicable.

Sensitivity was defined as =  $[TP / (TP + FN)] \times 100$ , where: TP (true positive) is the number of positive index test results in agreement with COVID-19 positivity, and FN (false negative) is the number of negative index test results discordant with COVID-19 positivity.

Specificity was defined as =  $[TN / (TN + FP)] \times 100$ , where TN (true negative) is the number of negative index test results in agreement with COVID-19 negativity, and FP (false positive) is number of positive index test results discordant with COVID-19 negativity.

The 95% confidence intervals were calculated to assess the level of uncertainty induced by sample size, using the Wilson's score method.

#### Regulatory and Ethics considerations:

An IRB approval was obtained prior to the execution of the study (UPCH IRB SIDISI: 202569). The study also was registered in the Peruvian COVID-19 study database PRISA (EI00000001341). The use of an informed consent was not necessary since all archived samples were collected from individuals who provided informed consent. All archived samples were de-identified and participant confidentiality was maintained.

The study was conducted in accordance with ethical principles derived from international guidelines including the Declaration of Helsinki, Good Clinical Practice Guidelines: ICH GCP E6 (R2) and local laws and regulations. The results from the tests under evaluation were used only for research purposes.

## RESULTS

A total of 199 samples were evaluated using the four antibody tests brands. Of these 199 samples, 99 of them were PCR positive for COVID-19 and the remaining 100 were from individuals who were unlikely to have had any exposure to SARS-CoV-2, these samples were obtained prior to November 2019. Table 2 shows the baseline characteristics of the participants whose samples were used in the study. There is relative homogeneity between both groups regarding sex, age, and presence of respiratory symptoms. The predominant upper respiratory symptom for both groups was the presence of cough (89% and 100%). The majority of the positive samples (50%) were collected within the participant's first week of symptoms.

Table 2. Basal characteristics of the participants whose samples were used for the analyses.

Characteristics	RT-PCR Positive N = 100	Pre-pandemic samples N = 100
Female (%)	47 (47%)	40 (40%)*
Median age in years (IQR)	35 (31-50)	31 (24-45)*
Respiratory symptoms (%)	89 (89%)	100 (100%)
Days of symptoms		
0 – 7 days	51 (50%)	NA
8 – 14 days	38 (38%)	NA
15 + days	12 (12%)	NA

\*These calculations are based on 98 RT-PCR Negative participants, the remaining 2 participants had missing data for gender and age.

NA: Non-applicable, these patients were suspected TB patients and they had more than 14 days of symptoms.

IQR: Interguartile range

Respiratory symptoms are considered any of the following: Cough, dyspnea, sore throat, fever, nasal congestion, or sputum production.

The sensitivity and specificity estimates for each test evaluated, overall and separated by antibody isotype (IgM, IgG, and IgM or IgG) and days of symptoms, are presented in Figure 1, sorted in descending order according to sensitivity. Across the entire specimen panel, the sensitivity ranged from 64% [95% CI: 54%-73%] to 29% [95% CI: 21%-39%]. However, the sensitivity of the tests varies when subset by days from symptom initiation as well as by isotype. The highest sensitivity is noted at 94% [95% CI: 84%-98%] for samples from subjects with 15+ days from symptom initiation, and the lowest sensitivity can be found at 3% [95% CI: 1%-17%] from subjects with 0-7 days from symptom initiation, consistent with the biological time course of antibody production. During the highest infectious period (0-7 days from symptom initiation) the highest sensitivity was 21% [95% CI: 10%-38%], and during the declining phase of the infectious period (8-14 days from symptom initiation) the highest sensitivity was 61% [95% CI: 39%-80%].

## Fig 1. Diagnostic accuracy of each antibody test and stratified by immunoglobulin antibody target and time since symptom onset.

TP: True positive, FP: False positive, TN: True negative, FN: False negative. IGG: detection of IgG line only; IGMorIGG: detection of IgG or IgM line; IGM: detection of IgM line only.

Regarding the isotype target, the overall sensitivity was higher when incorporating either IgM or IgG detection, followed by IgG and then IgM. As an example, the IgG antibody test from the brand Access Bio had a sensitivity of 57% [95% CI: 47%-66%] while the IgM antibody test had a sensitivity of 29% [95% CI: 21%-39%]. Only when >= 15 days have elapsed since symptom onset and either IgM or IgG is present does the LFIA sensitivity goes over 90% for all four brands. When considering IgM only, the highest sensitivity only reaches 54% [95% CI: 40%-67%]. A very high specificity (98% - 100%) was noted across all the tests evaluated.

## DISCUSSION

In the present study, we evaluated the diagnostic performance of 4 different brands of LFIA COVID-19 IgG/IgM rapid test cassettes. The sensitivity of these tests was calculated using blood samples from RT-PCR confirmed positive patients for SARS-CoV-2. Even though all the tests reached a high specificity performance, none of them reached an overall high sensitivity. Only when assessing the sensitivity in patients with 15+ days from symptom onset that all brands perform optimally, having a sensitivity over 90%, being 94% [95% CI: 84%-98%] the highest sensitivity found amongst the four brands.

Serological immunoassays have variable diagnostic accuracy. According to the literature, the pooled sensitivity for serology tests (measuring for IgG or IgM) for CLIA, ELISA, and LFIA was 97.8% (46.2% to 100%), 84.3% (95% CI 75.6% to 90.9%), and 66.0% (49.3% to 79.3%), respectively; with pool specificities from 96.6% to 99.7% (10). This has concordance with other meta-analyses, showing lower sensitivity for LFIA in comparison to CLIA and ELISA, and similar specificities between them (10,32,33). It is worth mentioning that for the overall sensitivity of our brands for IgM or IgG detection, our tests results are similar to previous meta-analyses sensitivity results (around 60%-75%) (33); however, the sensitivity found in patients with 15+ days from symptom initiation in our brands were higher than 90%, whereas previous meta-analyses of LFIA tests have found this sensitivity to be somewhere between 70-80% (10).

There are multiple reasons why the antibody tests may have a lower capacity to recognize a COVID-19 positive case. The timing of the test is one of the most documented in the literature. Even though levels of IgM and IgG have been reported to be found since the day 4 after the beginning of the symptoms, elevated and more detectable levels could be reached by the second and third week after symptom onset (34). IgM levels start to decline by the 4th week, and IgG levels remain way past the 7th week (34,35). This is also in accordance with our results where we found a low sensitivity for IgM and IgG detection in the first week, a higher

sensitivity for detection of IgM in the second week, and an even higher sensitivity for detection of IgG after the 15th day. This is also supported by past reports with antibody test positivity happening in the intermediate or last phase of the disease (36).

Additionally, although we documented minimal false positivity (high specificity) in our study, there may be limitations to the included samples. For example, it has been previously documented that there is potential for cross-reactivity between dengue viruses and SARS-CoV-2. Up to 22% of pre-pandemic samples from patients with a previous diagnosis of dengue showed a positive result for SARS-CoV-2 antibody testing (37). Given this estimate, caution should be exerted when using these antibody tests in tropical locations. As an example, a study that used LFIA antibody testing done in Peru, in the region of lquitos (part of the Peruvian Amazonian jungle), showed a 71% SARS-CoV-2 seroprevalence (38). Consequently, early on it was believed that lquitos could be getting closer to reach herd immunity levels (38, 39). However, this region is also known for having dengue as an endemic virus (40); as such, this high seroprevalence might have been affected, to some degree by a potential cross-reactivity. A similar high estimated COVID-19 seroprevalence has also been reported in other Amazon jungle cities of Brazil (Manaus, 66%)(41) and Colombia (Leticia, 62%)(42), however, the latter used an antibody test validated using COVID-19 negative samples from patients infected with Dengue and other arboviruses.

The most described potential use for the LFIA and serological COVID-19 tests are as tools for serosurveillance studies. LFIA has been reported to have high specificity, similar to ELISA, but reduced sensitivity, which makes it ideal for large seroprevalence studies, helping in the understanding of the propagation of the pandemic and in the build-up of vaccination programs from LMICs. Additionally, depending on the viral antigen antibody identified by the test, there could be a potential for differentiating vaccination status, (24-26); however, this should be used with caution depending on the days from symptom onset. Lastly, there are technologies evaluating the use of these LFIA antibody tests coupled with a spectrum-based reader (this

analyzes the line color intensity) to provide quantitative results that previously found a high correlation with a surrogate neutralization test (31,32), this could also be another venue for LFIA antibody testing use research.

#### CONCLUSION

We evaluated the diagnostic performance of 4 different brands of LFIA COVID-19 IgG/IgM rapid test cassettes in samples from Peruvian population. Consistent with previous literature, we confirmed they had an overall high specificity and a variable sensitivity depending on the days from symptom onset that was the highest after 14 days. All four immunological assays proved to be effective for identifying COVID-19 antibodies when two conditions were met: 1) at least 15 days have elapsed since symptom onset and 2) a sample is considered positive when either IgM or IgG is present. These LFIA antibody tests could be used for seroprevalence studies; however, attention should be put on the location where it would be employed and assess the potential for cross-reactivity with other endemic viral diseases. As well, caution with interpretation would be needed as these assays cannot distinguish between individuals who are seropositive due to prior infection or vaccination or both. Still, much information about immunity remains unknown. Future studies and LFIA point-of-care test manufacturers could aim to the identification of neutralizing antibodies, local accuracy considering endemic diseases, and its ability to detect and differentiate vaccinated and previously infected people, in order to find more and better uses for the serological COVID-19 tests (32, 43–45).

## REFERENCES

- 1. WHO Coronavirus (COVID-19) Dashboard [Internet]. [cited 2022 Oct 25]. Available from: https://covid19.who.int
- 2. Kevadiya BD, Machhi J, Herskovitz J, Oleynikov MD, Blomberg WR, Bajwa N, et al. Diagnostics for SARS-CoV-2 infections. Nat Mater [Internet]. 2021 May;20(5):593-605. Available from: http://dx.doi.org/10.1038/s41563-020-00906-z
- 3. Peeling RW. Olliaro PL. Boeras DI. Fongwen N. Scaling up COVID-19 rapid antigen tests: promises and challenges. Lancet Infect Dis [Internet]. 2021 Sep;21(9):e290-5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1473309921000487
- 4. Cheng ZJ, Li B, Zhan Z, Zhao Z, Xue M, Zheng P, et al. Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy. Clin Rev Allergy Immunol [Internet]. 2022 Jan 15; Available from: http://dx.doi.org/10.1007/s12016-021-08912-y
- 5. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature [Internet]. 2020 Aug;584(7821):437-42. Available from: http://dx.doi.org/10.1038/s41586-020-2456-9
- 6. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell [Internet]. 2020 Jun 25;181(7):1489-1501.e15. Available from: http://dx.doi.org/10.1016/i.cell.2020.05.015
- 7. Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, et al. Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis [Internet]. 2020 Nov 19;71(16):2255-8. Available from: http://dx.doi.org/10.1093/cid/ciaa489
- 8. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature [Internet]. 2020 May;581(7809):465-9. Available from: http://dx.doi.org/10.1038/s41586-020-2196-x
- 9. Ejazi SA, Ghosh S, Ali N. Antibody detection assays for COVID-19 diagnosis: an early overview. Immunol Cell Biol [Internet]. 2021 Jan:99(1):21-33. Available from: http://dx.doi.org/10.1111/imcb.12397
- 10. Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui L-P, Johnston JC, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and metaanalysis. BMJ [Internet]. 2020 Jul 1:370:m2516. Available from: http://dx.doi.org/10.1136/bmj.m2516
- 11. Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet [Internet]. 2020 Nov 14;396(10262):1595-606. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673620321371
- 12. Baumgarth N, Nikolich-Žugich J, Lee FE-H, Bhattacharya D. Antibody Responses to SARS-CoV-2: Let's Stick to Known Knowns. J Immunol [Internet]. 2020 Nov 1;205(9):2342–50. Available from: http://dx.doi.org/10.4049/jimmunol.2000839
- 13. Cheng MP, Yansouni CP, Basta NE, Desjardins M, Kanjilal S, Paquette K, et al. Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus 2 : A Narrative Review. Ann Intern Med [Internet]. 2020 Sep 15;173(6):450-60. Available from: http://dx.doi.org/10.7326/M20-2854
- 14. Vidal-Anzardo M, Solis G, Solari L, Minaya G, Ayala-Quintanilla B, Astete-Cornejo J, et al. Evaluation of a rapid serological test for detection of IgM and igG antibodies against SARS-CoV-2 under field conditions. Rev Peru Med Exp Salud Publica [Internet]. 2020 Apr;37(2):203-9. Available from: http://dx.doi.org/10.17843/rpmesp.2020.372.5534
- 15. Arenas CG, Montenegro-Idrogo JJ, Chiappe-Gonzalez AJ, Torre JCG de la.

[Considerations on the evaluation under field conditions of a rapid test for detection of IgM and IgG antibodies against SARS-CoV-2]. Rev Peru Med Exp Salud Publica [Internet]. 2020 Dec 2;37(3):571-2. Available from: http://dx.doi.org/10.17843/rpmesp.2020.373.5753

- 16. Vidal-Anzardo M, Solis G, Solari L, Minava G, Avala-Quintanilla B, Astete-Corneio J. et al. [Reply: considerations on the evaluation under field conditions of a rapid test for detection of IgM and IgG antibodies against SARS-CoV-2]. Rev Peru Med Exp Salud Publica [Internet]. 2020 Dec 2:37(3):573-4. Available from: http://dx.doi.org/10.17843/rpmesp.2020.373.5918
- 17. CHRISTINE ARMARIO Associated Press. Peru bet on cheap COVID antibody tests: it didn't go well [Internet]. ABC News. 2020 [cited 2022 Feb 15]. Available from: https://abcnews.go.com/Politics/wireStory/peru-bet-cheap-covid-antibody-tests-73480148
- 18. Valentín Ortiz LJ, Román AS, Público) EC (ojo, Público) GH (ojo. Rapid tests and false negatives: Puerto Rico and Peru's strategies to defeat COVID-19 [Internet]. Centro de Periodismo Investigativo. 2020 [cited 2022 Feb 15]. Available from: https://periodismoinvestigativo.com/2020/08/rapid-tests-and-false-negatives-puertorico-and-perus-strategies-to-defeat-covid-19/
- 19. Zhou L, Li C, Yang H, Yuan H, Pan M, Cheng X, et al. SARS-CoV-2 Seroprevalence and Profiles Among Convalescents in Sichuan Province, China. Front Public Health 2021 Oct 26;9:716483. Available [Internet]. from: http://dx.doi.org/10.3389/fpubh.2021.716483
- 20. Mijović B, Mašić S, Petković M, Knežević D, Aćimović J, Djaković-Dević J, et al. Seroprevalence of SARS-CoV-2 antibodies and knowledge, attitude and practice toward COVID-19 in the Republic of Srpska-Bosnia & Herzegovina: A populationbased study. PLoS One [Internet]. 2022 Jan 28;17(1):e0262738. Available from: http://dx.doi.org/10.1371/journal.pone.0262738
- 21. Puchades A, Daniel R, Geen J, Peden J, Lewis H, Nnoaham K. SARS-CoV-2 seroprevalence in the workforces of three large workplaces in South Wales: a seroepidemiological study. BMC Public Health [Internet]. 2022 Jan 24:22(1):162. Available from: http://dx.doi.org/10.1186/s12889-021-12478-x
- 22. Chapuy-Regaud S, Miédougé M, Abravanel F, Da Silva I, Porcheron M, Fillaux J, et al. Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays. Microbiol Spectr [Internet]. 2021 Dec 22;9(3):e0137621. Available from: http://dx.doi.org/10.1128/spectrum.01376-21
- 23. Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med [Internet]. 2021 Apr 8:384(14):1372-4. Available from: http://dx.doi.org/10.1056/NEJMc2101667
- 24. Fotis C, Meimetis N, Tsolakos N, Politou M, Akinosoglou K, Pliaka V, et al. Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays. Sci Rep [Internet], 2021 Mar 23:11(1):6614. Available from: http://dx.doi.org/10.1038/s41598-021-86035-2
- 25. CDC. Interim Guidelines for COVID-19 Antibody Testing [Internet]. Centers for Disease Prevention. 2022 [cited 2022 Feb Available from: Control and 15]. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-testsguidelines.html
- 26. Montesinos I, Dahma H, Wolff F, Dauby N, Delaunoy S, Wuyts M, et al. Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests. J Clin Virol [Internet]. 2021 Nov;144:104988. Available from: http://dx.doi.org/10.1016/j.jcv.2021.104988
- 27. Luchsinger LL, Ransegnola BP, Jin DK, Muecksch F, Weisblum Y, Bao W, et al. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. J Clin Microbiol [Internet]. 2020 Nov 18;58(12). Available from: http://dx.doi.org/10.1128/JCM.02005-20

- 28. Grenache DG, Ye C, Bradfute SB. Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological Immunoassay. J Appl Lab Med [Internet]. 2021 Mar 1;6(2):491-5. Available from: http://dx.doi.org/10.1093/ialm/ifaa195
- 29. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Clinical performance of different SARS-CoV-2 IgG antibody tests. J Med Virol [Internet]. 2020 Oct:92(10):2243-7. Available from: http://dx.doi.org/10.1002/jmv.26145
- 30. Huang R-L, Fu Y-C, Wang Y-C, Hong C, Yang W-C, Wang I-J, et al. A lateral flow immunoassay coupled with a spectrum-based reader for SARS-CoV-2 neutralizing antibody detection. Vaccines (Basel) [Internet]. 2022 Feb 10;10(2):271. Available from: https://www.mdpi.com/2076-393X/10/2/271
- 31. Hung K-F, Hung C-H, Hong C, Chen S-C, Sun Y-C, Wen J-W, et al. Quantitative Spectrochip-Coupled Lateral Flow Immunoassay Demonstrates Clinical Potential for Disease 2019 Overcoming Coronavirus Pandemic Screening Challenges. Micromachines (Basel) [Internet]. 2021 Mar 18;12(3). Available from: http://dx.doi.org/10.3390/mi12030321
- 32. Vengesai A. Midzi H. Kasambala M. Mutandadzi H. Mduluza-Jokonva TL. Rusakaniko S, et al. A systematic and meta-analysis review on the diagnostic accuracy of antibodies in the serological diagnosis of COVID-19. Syst Rev [Internet]. 2021 May 26;10(1):155. Available from: http://dx.doi.org/10.1186/s13643-021-01689-3
- 33. Wang H, Ai J, Loeffelholz MJ, Tang Y-W, Zhang W. Meta-analysis of diagnostic performance of serology tests for COVID-19: impact of assay design and postsymptom-onset intervals. Emerg Microbes Infect [Internet]. 2020 Dec;9(1):2200-11. Available from: http://dx.doi.org/10.1080/22221751.2020.1826362
- 34. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. 9;323(22):2249-51. JAMA [Internet]. 2020 Available Jun from: http://dx.doi.org/10.1001/jama.2020.8259
- 35. Xiao AT, Gao C, Zhang S. Profile of specific antibodies to SARS-CoV-2: The first Jul;81(1):147-78. report. Infect [Internet]. 2020 Available from: J http://dx.doi.org/10.1016/j.jinf.2020.03.012
- 36. Uwamino Y, Wakui M, Aoki W, Kurafuji T, Yanagita E, Morita M, et al. Evaluation of the usability of various rapid antibody tests in the diagnostic application for COVID-19. Ann Clin Biochem [Internet]. 2021 May;58(3):174-80. Available from: http://dx.doi.org/10.1177/0004563220984827
- 37. Lustig Y, Keler S, Kolodny R, Ben-Tal N, Atias-Varon D, Shlush E, et al. Potential antigenic cross-reactivity between severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) and dengue viruses. Clin Infect Dis [Internet]. 2021 Oct 5:73(7):e2444-9. Available from: http://dx.doi.org/10.1093/cid/ciaa1207
- 38. Álvarez-Antonio C, Meza-Sánchez G, Calampa C, Casanova W, Carey C, Alava F, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Iguitos, Peru in July and August, 2020: a population-based study. Lancet Glob Health [Internet]. 2021 Jul;9(7):e925-31. Available from: http://dx.doi.org/10.1016/S2214-109X(21)00173-X
- 39. Chenet SM, Tapia-Limonchi R. Reaching the theoretical herd immunity threshold in Iquitos, Peru: are seroprevalence data enough? Lancet Glob Health [Internet]. Elsevier BV; Jul;9(7):e881-2. Available from: http://dx.doi.org/10.1016/S2214-2021 109X(21)00203-5
- 40. Stoddard ST, Wearing HJ, Reiner RC Jr, Morrison AC, Astete H, Vilcarromero S, et al. Long-term and seasonal dynamics of dengue in Iguitos, Peru. PLoS Negl Trop Dis [Internet]. 2014 Jul:8(7):e3003. Available from: http://dx.doi.org/10.1371/journal.pntd.0003003
- 41. Buss LF, Prete CA Jr, Abrahim CMM, Mendrone A Jr, Salomon T, de Almeida-Neto C, et al. COVID-19 herd immunity in the Brazilian Amazon [Internet]. bioRxiv. medRxiv; 2020. Available from: http://dx.doi.org/10.1101/2020.09.16.20194787
- 42. Mercado-Reyes M, Malagón-Rojas J, Rodríguez-Barraquer I, Zapata-Bedoya S, Wiesner M, Cucunubá Z, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in

Colombia, 2020: A population-based study. Lancet Reg Health Am [Internet]. 2022 May;9(100195):100195. Available from: http://dx.doi.org/10.1016/j.lana.2022.100195

- 43. Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis. Diagnostics (Basel) [Internet]. 2020 May 19:10(5). Available from: http://dx.doi.org/10.3390/diagnostics10050319
- 44. Rivera-Olivero IA, Henríquez-Trujillo AR, Kyriakidis NC, Ortiz-Prado E, Laglaguano JC, Vallejo-Janeta AP, et al. Diagnostic Performance of Seven Commercial COVID-19 Serology Tests Available in South America. Front Cell Infect Microbiol [Internet]. 2022 Feb 18;12:787987. Available from: http://dx.doi.org/10.3389/fcimb.2022.787987
- 45. Owen SI, Williams CT, Garrod G, Fraser AJ, Menzies S, Baldwin L, et al. Twelve lateral flow immunoassays (LFAs) to detect SARS-CoV-2 antibodies. J Infect [Internet]. 2022 Mar;84(3):355-60. Available from: http://dx.doi.org/10.1016/j.jinf.2021.12.007

Group	Test	Ν	TP	FP	ΤN	FN	Sensitivity [95% CI]	Specificity [95% CI]	
All	All								
	CTK_Biotech_Inc_IGMorIGG	195	61	2	98	34	0.64 [0.54-0.73]	0.98 [0.93–0.99]	
	Biosynex_SA_IGMorIGG	199	62	0	100	37	0.63 [0.53-0.72]	1.00 [0.96–1.00]	
	Access_Bio_IGMorIGG	199	60	0	100	39	0.61 [0.51-0.70]	1.00 [0.96–1.00]	
	Bionote_IGMorIGG	199	60	0	100	39	0.61 [0.51-0.70]	1.00 [0.96–1.00]	
	Access_Bio_IGG	199	56	0	100	43	0.57 [0.47-0.66]	1.00 [0.96–1.00]	
	Bionote_IGG	199	55	0	100	44	0.56 [0.46-0.65]	1.00 [0.96–1.00]	
	CTK_Biotech_Inc_IGG	196	52	0	100	44	0.54 [0.44-0.64]	1.00 [0.96–1.00]	
	Biosynex_SA_IGG	199	53	0	100	46	0.54 [0.44-0.63]	1.00 [0.96–1.00]	
	CTK_Biotech_Inc_IGM	196	40	2	98	56	0.42 [0.32-0.52]	0.98 [0.93-0.99]	
	Biosynex_SA_IGM	199	40	0	100	59	0.40 [0.31-0.50]	1.00 [0.96–1.00]	
	Bionote_IGM	199	30	0	100	69	0.30 [0.22-0.40]	1.00 [0.96–1.00]	
	Access_Bio_IGM	199	29	0	100	70	0.29 [0.21-0.39]	1.00 [0.96–1.00]	
Day 0-7									
	CTK_Biotech_Inc_IGMorIGG	29	6	0	0	23	0.21 [0.10-0.38]	<b></b>	
	Biosynex_SA_IGMorIGG	29	5	0	0	24	0.17 [0.08-0.35]	<b>⊢</b> ∎ → 1	
	medRxiv preprint doi: https://doi.org/10.1101/2023.01.13.23284518; this version posted January 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in								
Biosynex_SA_IGM 2It is made available under a CCBNG4.0. International license .									
	Bionote_IGMorIGG	29	4	0	0	25	0.14 [0.06-0.31]	<b>⊢</b> ∎−−−1	
	CTK_Biotech_Inc_IGM	29	4	0	0	25	0.14 [0.06-0.31]	L	
	Access_Bio_IGG	29	3	0	0	26	0.10 [0.04-0.26]	- <b></b>	
	Bionote_IGG	29	3	0	0	26	0.10 [0.04-0.26]		
	Access_Bio_IGM	29	2	0	0	27	0.07 [0.02-0.22]	H	
	Bionote_IGM	29	2	0	0	27	0.07 [0.02-0.22]	H=	
	CTK_Biotech_Inc_IGG	29	2	0	0	27	0.07 [0.02-0.22]	H	
	Biosynex_SA_IGG	29	1	0	0	28	0.03 [0.01-0.17]	H	
Day 8-14	1								
	CTK_Biotech_Inc_IGMorIGG	18	11	0	0	7	0.61 [0.39-0.80]	P	
	Biosynex_SA_IGMorIGG	20	11	0	0	9	0.55 [0.34-0.74]	P	
	CTK_Biotech_Inc_IGM	19	10	0	0	9	0.53 [0.32-0.73]	<b></b>	
	Biosynex_SA_IGM	20	10	0	0	10	0.50 [0.30-0.70]	<b>⊢</b>	
	Bionote_IGMorIGG	20	10	0	0	10	0.50 [0.30-0.70]		
	Access_Bio_IGMorIGG	20	9	0	0	11	0.45 [0.26-0.66]	<b>→</b>	
	Bionote_IGM	20	7	0	0	13	0.35 [0.18-0.57]		

---------

-

## Day 15+

CTK\_Biotech\_Inc\_IGG

Access\_Bio\_IGM

Access\_Bio\_IGG

Biosynex\_SA\_IGG

Bionote\_IGG

Access_Bio_IGG	50	47	0	0	3	0.94 [0.84-0.98]
Access_Bio_IGMorIGG	50	47	0	0	3	0.94 [0.84-0.98]
Biosynex_SA_IGG	50	46	0	0	4	0.92 [0.81-0.97]
Biosynex_SA_IGMorIGG	50	46	0	0	4	0.92 [0.81-0.97]
Bionote_IGG	50	46	0	0	4	0.92 [0.81-0.97]
Bionote_IGMorIGG	50	46	0	0	4	0.92 [0.81-0.97]
CTK_Biotech_Inc_IGG	48	44	0	0	4	0.92 [0.80-0.97]
CTK_Biotech_Inc_IGMorIGG	48	44	0	0	4	0.92 [0.80-0.97]
CTK_Biotech_Inc_IGM	48	26	0	0	22	0.54 [0.40-0.67]
Biosynex_SA_IGM	50	26	0	0	24	0.52 [0.39-0.65]
Access_Bio_IGM	50	21	0	0	29	0.42 [0.29-0.56]
Bionote_IGM	50	21	0	0	29	0.42 [0.29-0.56]

19 6 0 0 13 0.32 [0.15-0.54]

20 6 0 0 14 0.30 [0.15-0.52]

14 0.30 [0.15-0.52]


14 0.30 [0.15-0.52]

14 0.30 [0.15-0.52]

20 6 0 0

20 6 0 0

20 6 0 0



-----

-1

# Figure